Anti-DEPTOR antibody produced in rabbit

Description

• General description: DEPTOR (DEP domain containing MTOR-interacting protein) is a tumor suppressor and mTOR-binding protein. This protein is expressed in vascular endothelial cells.
• Immunogen: DEP domain-containing protein 6 recombinant protein epitope signature tag (PrEST)
• Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies® protocols and other useful information.
• Biochem/physiol Actions: DEPTOR (DEP domain containing MTOR-interacting protein) suppresses mTORC1(mammalian target of rapamycin complex 1) and mTORC2 proteins which are responsible for the control of cell growth, metabolism, proliferation and survival. It is expressed in normal pancreatic acinar and islet cells, and this expression is completely lost in pancreatic ductal adenocarcinoma (PDAC) tissues. Therefore, it functions as a tumor suppressor in pancreatic cancer. It is regulator of inflammatory and angiogenic responses and controls the activation of vascular endothelial cells. DEPTOR is expressed in placenta, and DEPTOR signaling is influenced by maternal stress which might eventually impact the outcome of pregnancy. The expression of this protein is reduced in thyroid, prostate, bladder and cervical cancer.
• Features and Benefits: Prestige Antibodies® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.Every Prestige Antibody is tested in the following ways:IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.Protein array of 364 human recombinant protein fragments.
• Linkage: Corresponding Antigen APREST76297
• Physical form: Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide
• Legal Information: Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany